HIV Reservoir Dynamics During Antiretroviral Therapy (The HIV Eradication and Latency [HEAL] Cohort)

  • Principal Investigator(s): Athe Tsibris
  • Study Contact:, Athe Tsibris, atsibris@bwh.harvard.edu
  • Description of Subjects: Virologically suppressed participants with HIV
  • Location (Domestic vs. International): Boston, MA (BWH, MGH, BMC)
  • Enrollment Period: 2015
  • Enrollment Goal: 200
  • Key Exclusion and Inclusion Criteria: HIV infection, must be taking (or expected to begin taking) a combination antiretroviral therapy regimen, hemoglobin ≥ 8.0 g/dL. Excludes need for systemic chemotherapy, bone marrow transplant, pregnancy, and need for immunosuppressive therapy
  • Available Biological Specimens and Data: Yes, Blood, serum, or plasma, Peripheral Blood Mononuclear Cells, Other (leukapheresis samples)
  • How to Request Access: email HEAL PI directly
  • Available Data Description: CD4 counts, virus loads, treatment history, duration of therapy, duration of virologic suppression.
  • Other Information: Gut and skin biopsies will be added in future